Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
4 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
OnabotulinumtoxinA Reduces Health Resource Utilization in Chronic Migraine: PREDICT Study.
Can J Neurol Sci. 2023 May;50(3):418-427. doi: 10.1017/cjn.2022.43. Epub 2022 Apr 25.
Can J Neurol Sci. 2023.
PMID: 35466897
OnabotulinumtoxinA Improves Quality of Life in Chronic Migraine: The PREDICT Study.
Boudreau G, Finkelstein I, Graboski C, Ong M, Christie S, Sommer K, Bhogal M, Davidovic G, Becker WJ.
Boudreau G, et al. Among authors: graboski c.
Can J Neurol Sci. 2022 Jul;49(4):540-552. doi: 10.1017/cjn.2021.153. Epub 2021 Jul 5.
Can J Neurol Sci. 2022.
PMID: 34218836
Item in Clipboard
OnabotulinumtoxinA Improves Quality of Life in Chronic Migraine: The PREDICT Study - CORRIGENDUM.
Boudreau G, Finkelstein I, Graboski C, Ong M, Christie S, Sommer K, Bhogal M, Davidovic G, Becker WJ.
Boudreau G, et al. Among authors: graboski c.
Can J Neurol Sci. 2024 Jan;51(1):149. doi: 10.1017/cjn.2023.317. Epub 2023 Dec 18.
Can J Neurol Sci. 2024.
PMID: 38105013
No abstract available.
Item in Clipboard
Botulinum toxin A versus bupivacaine trigger point injections for the treatment of myofascial pain syndrome: a randomised double blind crossover study.
Graboski CL, Gray DS, Burnham RS.
Graboski CL, et al.
Pain. 2005 Nov;118(1-2):170-5. doi: 10.1016/j.pain.2005.08.012. Epub 2005 Oct 3.
Pain. 2005.
PMID: 16202527
Clinical Trial.
Item in Clipboard
Cite
Cite